Last reviewed · How we verify

treatment Doxorubicin

Assistance Publique Hopitaux De Marseille · Phase 3 active Small molecule

treatment Doxorubicin is a Anthracycline chemotherapy agent Small molecule drug developed by Assistance Publique Hopitaux De Marseille. It is currently in Phase 3 development for Breast cancer, Lymphomas, Leukemias.

Doxorubicin intercalates into DNA and inhibits topoisomerase II, preventing DNA replication and transcription in cancer cells.

Doxorubicin intercalates into DNA and inhibits topoisomerase II, preventing DNA replication and transcription in cancer cells. Used for Breast cancer, Lymphomas, Leukemias.

At a glance

Generic nametreatment Doxorubicin
SponsorAssistance Publique Hopitaux De Marseille
Drug classAnthracycline chemotherapy agent
TargetDNA (intercalating agent); Topoisomerase II
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Doxorubicin is an anthracycline chemotherapy agent that inserts itself between DNA base pairs (intercalation) and blocks topoisomerase II, an enzyme essential for DNA unwinding and repair. This dual mechanism leads to DNA strand breaks, cell cycle arrest, and apoptosis in rapidly dividing cancer cells. It also generates reactive oxygen species that contribute to its cytotoxic effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about treatment Doxorubicin

What is treatment Doxorubicin?

treatment Doxorubicin is a Anthracycline chemotherapy agent drug developed by Assistance Publique Hopitaux De Marseille, indicated for Breast cancer, Lymphomas, Leukemias.

How does treatment Doxorubicin work?

Doxorubicin intercalates into DNA and inhibits topoisomerase II, preventing DNA replication and transcription in cancer cells.

What is treatment Doxorubicin used for?

treatment Doxorubicin is indicated for Breast cancer, Lymphomas, Leukemias, Sarcomas, Ovarian cancer.

Who makes treatment Doxorubicin?

treatment Doxorubicin is developed by Assistance Publique Hopitaux De Marseille (see full Assistance Publique Hopitaux De Marseille pipeline at /company/assistance-publique-hopitaux-de-marseille).

What drug class is treatment Doxorubicin in?

treatment Doxorubicin belongs to the Anthracycline chemotherapy agent class. See all Anthracycline chemotherapy agent drugs at /class/anthracycline-chemotherapy-agent.

What development phase is treatment Doxorubicin in?

treatment Doxorubicin is in Phase 3.

What are the side effects of treatment Doxorubicin?

Common side effects of treatment Doxorubicin include Cardiotoxicity / cardiomyopathy, Myelosuppression (neutropenia, anemia, thrombocytopenia), Nausea and vomiting, Alopecia (hair loss), Mucositis, Diarrhea.

What does treatment Doxorubicin target?

treatment Doxorubicin targets DNA (intercalating agent); Topoisomerase II and is a Anthracycline chemotherapy agent.

Related